Abstract
Nonsense mutations promote premature translational termination and cause anywhere from 5–70% of the individual cases of most inherited diseases1. Studies on nonsense-mediated cystic fibrosis have indicated that boosting specific protein synthesis from <1% to as little as 5% of normal levels may greatly reduce the severity or eliminate the principal manifestations of disease2,3. To address the need for a drug capable of suppressing premature termination, we identified PTC124—a new chemical entity that selectively induces ribosomal readthrough of premature but not normal termination codons. PTC124 activity, optimized using nonsense-containing reporters, promoted dystrophin production in primary muscle cells from humans and mdx mice expressing dystrophin nonsense alleles, and rescued striated muscle function in mdx mice within 2–8 weeks of drug exposure. PTC124 was well tolerated in animals at plasma exposures substantially in excess of those required for nonsense suppression. The selectivity of PTC124 for premature termination codons, its well characterized activity profile, oral bioavailability and pharmacological properties indicate that this drug may have broad clinical potential for the treatment of a large group of genetic disorders with limited or no therapeutic options.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
185,98 € per year
only 3,65 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mendell, J. T. & Dietz, H. C. When the message goes awry: disease-producing mutations that influence mRNA content and performance. Cell 107, 411–414 (2001)
Kerem, E. Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr. Opin. Pulm. Med. 10, 547–552 (2004)
Ramalho, A. S. et al. Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 27, 619–627 (2002)
Maquat, L. E. Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nature Rev. Mol. Cell Biol. 5, 89–99 (2004)
Amrani, N. Sachs M. S. & Jacobson, A. Early nonsense: mRNA decay solves a translational problem. Nature Rev. Mol. Cell Biol. 7, 415–425 (2006)
Welch, E. M., Wang, W. & Peltz, S. W. in Translational Control of Gene Expression (eds Sonenberg, N., Hershey, J. W. B. & Mathews, M. B.) 467–486 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2000)
Maderazo, A. B., He, F., Mangus, D. A. & Jacobson, A. Upf1p control of nonsense mRNA translation is regulated by Nmd2p and Upf3p. Mol. Cell. Biol. 20, 4591–4603 (2000)
Weng, Y., Czaplinski, K. & Peltz, S. W. Genetic and biochemical characterization of mutations in the ATPase and helicase regions of the Upf1 protein. Mol. Cell. Biol. 16, 5477–5490 (1996)
Weng, Y., Czaplinski, K. & Peltz, S. W. Identification and characterization of mutations in the UPF1 gene that affect nonsense suppression and the formation of the Upf protein complex but not mRNA turnover. Mol. Cell. Biol. 16, 5491–5506 (1996)
Wang, W., Czaplinski, K., Rao, Y. & Peltz, S. W. The role of Upf proteins in modulating the translation read-through of nonsense-containing transcripts. EMBO J. 20, 880–890 (2001)
Manuvakhova, M., Keeling, K. & Bedwell, D. M. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6, 1044–1055 (2000)
Politano, L. et al. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol. 22, 15–21 (2003)
Clancy, J. P. et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 163, 1683–1692 (2001)
Wilschanski, M. et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. 349, 1433–1441 (2003)
Wagner, K. R. et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann. Neurol. 49, 706–711 (2001)
Barton-Davis, E. R., Cordier, L., Shoturma, D. I., Leland, S. E. & Sweeney, H. L. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest. 104, 375–381 (1999)
Bonetti, B., Fu, L., Moon, J. & Bedwell, D. M. The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae. J. Mol. Biol. 251, 334–345 (1995)
McCaughan, K. K., Brown, C. M., Dalphin, M. E., Berry, M. J. & Tate, W. P. Translational termination efficiency in mammals is influenced by the base following the stop codon. Proc. Natl Acad. Sci. USA 92, 5431–5435 (1995)
Howard, M. T. et al. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann. Neurol. 48, 164–169 (2000)
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M. & Sweeney, H. L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl Acad. Sci. USA 90, 3710–3714 (1993)
Jacobson, A. & Peltz, S. W. Interrelationships of the pathways of mRNA decay and translation in eukaryotic cells. Annu. Rev. Biochem. 65, 693–739 (1996)
Mendell, J. T., Sharifi, N. A., Meyers, J. L., Martinez-Murillo, F. & Dietz, H. C. Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise. Nature Genet. 36, 1073–1078 (2004)
Amrani, N. et al. A faux 3′-UTR promotes aberrant termination and triggers nonsense-mediated mRNA decay. Nature 432, 112–118 (2004)
Hirawat, S. et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J. Clin. Pharm. 47, 430–444 (2007)
He, F. et al. Genome-wide analysis of mRNAs regulated by the nonsense-mediated and 5′ to 3′ mRNA decay pathways in yeast. Mol. Cell 12, 1439–1452 (2003)
Pruitt, K. D. & Maglott, D. R. RefSeq and LocusLink: NCBI gene-centered resources. Nucleic Acids Res. 29, 137–140 (2001)
Frischmeyer, P. A. et al. An mRNA surveillance mechanism that eliminates transcripts lacking termination codons. Science 295, 2258–2261 (2002)
van Hoof, H. A., Frischmeyer, P. A., Dietz, H. C. & Parker, R. Exosome-mediated recognition and degradation of mRNAs lacking a termination codon. Science 295, 2262–2264 (2002)
Sambrook, J., Fritsch, E. & Maniatis, T. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. (1989)
Grentzmann, G., Ingram, J. A., Kelly, P. J., Gesteland, R. F. & Atkins, J. F. A dual-luciferase reporter system for studying recoding signals. RNA 4, 479–486 (1998)
Van Der Velden, V., Kaminski, A., Jackson, R. J. & Belsham, G. J. Defective point mutants of the encephalomyocarditis virus internal ribosome entry site can be complemented in trans. Virology 214, 82–90 (1995)
Jang, S. K. et al. A segment of the 5′-nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J. Virol. 62, 2636–2643 (1988)
Neville, C., Rosenthal, N., McGrew, M., Bogdanova, N. & Hauschka, S. in Methods in Cell Biology 52. (eds Sweeney H. L. and Emerson, C.) 85–116 (Academic Press, San Diego, 1998)
Sweeney, H. L. & Feng, H. Structure–function analysis of cytoskeletal/contractile proteins in avian myotubes. Methods Cell Biol. 52, 275–282 (1997)
O'Farrell, P. H. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. 250, 4007–4021 (1975)
Acknowledgements
This work was supported by an STTR grant to A.J. from the NIH and grants from the Muscular Dystrophy Association (USA) and Parent Project Muscular Dystrophy (USA) to H.L.S. We thank L. Cao and T. Komatsu for helpful discussions, G. Elfring for statistical support, D. Minn, X. Kang and S. Gothe for database mining and informatics expertise, and N. Garneau, S. I. Huq, and A. Bhattacharya for technical expertise. We thank K. Donnelly, C. Hirawat and F. P. Nigel for their effort, support and enthusiasm for the project. L. Gold, D. Goeddel and the late R. Swanson provided advice, encouragement and support at the onset of this project, which is gratefully acknowledged. We are grateful to the patients and their families and doctors for their participation in the clinical trial that generated the muscle biopsies and for their commitment during the development of PTC124.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
All authors have competing financial interests except E. Barton, P. Spatrick, F. He, M. Kawana and H. Feng.
Supplementary information
Supplementary Information
This file contains Supplementary Results, Supplementary Tables 1- 7, Supplementary Figures 1-7 with Legends and additional references. (PDF 649 kb)
Rights and permissions
About this article
Cite this article
Welch, E., Barton, E., Zhuo, J. et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447, 87–91 (2007). https://doi.org/10.1038/nature05756
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature05756
This article is cited by
-
Near-cognate tRNAs increase the efficiency and precision of pseudouridine-mediated readthrough of premature termination codons
Nature Biotechnology (2024)
-
Novel variants ensued genomic imprinting in familial central precocious puberty
Journal of Endocrinological Investigation (2024)
-
NGS-based targeted sequencing identified six novel variants in patients with Duchenne/Becker muscular dystrophy from southwestern China
BMC Medical Genomics (2023)
-
Synthesis of octahydropyrrolo[3,4-c]pyrroles by thermolysis of N-phthalimidoaziridines based on 5-alkenyl-1,2,4-oxadiazoles
Chemistry of Heterocyclic Compounds (2023)
-
Evolving Therapeutic Options for the Treatment of Duchenne Muscular Dystrophy
Neurotherapeutics (2023)